RS Oncology presents new drug in early clinical development for Mesothelioma and lung cancer patients
Retrieved on:
Thursday, August 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Anoxic waters, IMIG, Medical laboratory, University, University of Leicester, Mitochondrion, University Hospitals Cleveland Medical Center, Cancer, Quality of life, John Cunniff, Therapy, Multimedia, Research, Assistant, MPE, Science, PRX, ROS, Oxidative stress, University Hospitals of Leicester NHS Trust, RSO, Patient, Pathology, RS, Mesothelioma, NIHR, Science Publishing Group, Reactive oxygen species, Safety, Pharmaceutical industry
RS Oncology is bringing exciting new science to patients who will have the best chance of benefiting from new therapies.
Key Points:
- RS Oncology is bringing exciting new science to patients who will have the best chance of benefiting from new therapies.
- PRX3 is a novel drug target with potential for treating patients with the asbestos related cancer, mesothelioma.
- “PRX3 is a novel and interesting therapeutic drug target with potential for treating cancers, especially those with unmet need such as mesothelioma.
- We await the first clinical results with interest.”
For more information about MITOPE clinical trial visit Mesothelioma UK .